© 2020 MJH Life Sciences and HCPLive. All rights reserved.
Psoriatic Arthritis
Upadacitinib Demonstrates Safety and Efficacy for Atopic Dermatitis
July 21, 2020
Article
Upadacitinib 15 mg and 30 mg outperformed placebo in Measure Up 2, the second part of a phase 3 study on the monotherapy.
FDA Approves Guselkumab for Active Psoriatic Arthritis
July 14, 2020
Article
Guselkumab represents the first FDA approved medication for active psoriatic arthritis that selectively inhibits interleukin-23.
ACR Supports Use of Telemedicine for Rheumatology
July 01, 2020
Article
The statement contains positions and oppositions for telemedicine, along with highlights barriers and opportunities for patients and rheumatology professionals.
Vibeke Strand, MD: Important Rheumatology Data Coming Out of EULAR
June 11, 2020
Article
Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.
Vibeke Strand, MD: Comorbidities Make Treating Psoriatic Arthritis Difficult
June 11, 2020
Article
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.
Philip Mease, MD: Taking Conferences Virtual in the Age of COVID-19
June 08, 2020
Article
Dr. Philip Mease explains the next steps for testing the efficacy and safety of upadacitinib for patients with psoriatic arthritis.
Dennis McGonagle, PhD: The Future of Guselkumab for Psoriatic Arthritis
June 08, 2020
Article
Dr. Dennis McGonagle said guslekumab is also being tested in patients with inflammatory bowel disease.
Philip Mease, MD: The Relationship Between Psoriatic Arthritis and IBD
June 07, 2020
Article
Dr. Philip Mease discusses some of the treatments currently being tested for effectiveness against COVID-19.
Philip Mease, MD: Upadacitinib Showing Promise Treating Psoriatic Arthritis
June 07, 2020
Article
Dr. Philip Mease explains the relationship between rheumatoid arthritis and psoriatic arthritis.
Ixekizumab Improves Signs and Symptoms of Psoriatic Arthritis
June 06, 2020
Article
The safety profile is consistent with previous studies of the ixekizumab.